# Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma

> **NCT01100242** · PHASE2 · TERMINATED · sponsor: **New Mexico Cancer Research Alliance** · enrollment: 17 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Velcade and Sorafenib

## Key facts

- **NCT ID:** NCT01100242
- **Lead sponsor:** New Mexico Cancer Research Alliance
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04
- **Primary completion:** 2014-01
- **Final completion:** 2015-02
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2015-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01100242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01100242, "Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01100242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*